Corvus Pharmaceuticals (CRVS) Common Equity (2015 - 2026)

Corvus Pharmaceuticals' Common Equity history runs 12 years deep, the most recent figure standing at $240.7 million for Q1 2026.

• On a quarterly basis, Common Equity rose 387.95% year-over-year to $240.7 million in Q1 2026; TTM through Mar 2026 was $240.7 million, a 387.95% increase from a year earlier, with the FY2025 full-year figure at $61.2 million, up 87.93% from the prior year.
• Common Equity rose to $240.7 million in Q1 2026 per CRVS's latest filing, from $61.2 million in the prior quarter.
• Across five years, Common Equity topped out at $240.7 million in Q1 2026 and bottomed at $12.4 million in Q3 2024.
• The 5-year median for Common Equity is $51.2 million (2024), against an average of $65.0 million.
• Across the five-year window, Common Equity plunged 71.98% in 2024 and soared 478.35% in 2025, its largest moves.
• Year by year, Common Equity stood at $56.1 million in 2022, then slumped by 31.06% to $38.7 million in 2023, then fell by 15.81% to $32.6 million in 2024, then jumped by 87.93% to $61.2 million in 2025, then jumped by 293.23% to $240.7 million in 2026.
• Per Business Quant, the three latest CRVS Common Equity figures stand at $240.7 million (Q1 2026), $61.2 million (Q4 2025), and $71.8 million (Q3 2025).